HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.

2nd Edition of Global Conference on Gynecology & Women's Health

October 17-19, 2024 | Baltimore, Maryland, USA

October 17 -19, 2024 | Baltimore, Maryland, USA
Gynec 2023

Nadezhda Pavlova

Speaker at Gynaecologic Oncology - Nadezhda Pavlova
Belgorod State University, Russian Federation
Title : Associations of polymorphic loci of matrix metalloproteinase genes with the breast cancer in women of Russia

Abstract:

The aim of the study was to detect the interlocus interactions of the MMPs genes associated with breast cancer (BC). Material and methods. The study included 358 patients with breast cancer (68 patients had a burdened family history) and 746 women of the control group. The examination of women was carried out in the Regional Oncological Dispensary in Belgorod. Genotyping of 10 polymorphic loci of MMP genes (rs1799750 MMP1; rs243865 MMP2; rs679620 MMP3; rs1940475 MMP8; rs17576, rs17577, rs3918242, rs2250889, rs3787268, rs3918249 MMP9) was performed. To study the associations of polymorphic variants of MMP genes with BC in two subgroups, taking into account the presence/absence of a burdened family history (the control group for these two subgroups was the same) and were evaluated in the PLINK program using the logistic regression method. Results. It was revealed that a low BC risk among women with a burdened family history was associated with polymorphisms rs243865 MMP2 (OR=0.53–0.54, pperm ≤ 0.03) and rs2250889 MMP9 (OR=0.36–0.37, pperm ≤ 0.04). In women without burdened heredity, an increased BC risk was associated with rs3787268 MMP9 (OR=2.16, pperm=0.03) and haplotypes of polymorphic loci of the MMP9 gene (pperm≤0.05): CA rs3918249–rs17576 (OR=2.15), CCA rs3918242– rs3918249–rs17576 (OR=1.69), CCAG rs3918242–rs3918249–rs17576–rs3787268 (OR=1.69), CAGCG rs3918249–rs17576–rs3787268–rs2250889–rs17577 (OR=3.06). Three haplotypes were associated with a low BC risk in women without burdened heredity: GG rs17576–rs3787268 (OR = 0.60), GGC rs17576–rs3787268–rs2250889 (OR=0.63), and CGG rs3918249–rs17576–rs3787268 (OR=0.62).

Biography:

Dr. Nadezhda Pavlova qualified as a doctor at Belgorod State University in 2005. Since 2006, she has been working as oncologist in Belgorod Regional Oncological Dispensary. Since 2018 she is a deputy chief physician in outpatient service of Belgorod Regional Oncological Dispensary. She is a candidate for the degree of Candidate of Medical Sciences (Ph.D). She has more than 30 scientific papers in the field of studying breast cancer development, treatment and prognosis.

Watsapp